



Stephan Forchhammer

Kontakt

Stephan Forchhammer

Publikationen (10)

Knopf P, Stowbur D, Hoffmann S, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, Sinharay S, Fehrenbacher B, Gonzalez-Menendez I, Reckmann F, Bomze D, Flatz L, Kramer D, Schaller M, Forchhammer S, Bhujwala Z, Quintanilla-Martinez L, Schulze-Osthoff K, Pagel M, Fransen M, Röcken M, Martins A, Pichler B, Ghoreschi K, Kneilling M. Acidosis-mediated increase in IFN- γ -induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. *Mol Cancer* 2023; 22:207.

Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. *J Am Acad Dermatol* 2023

Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. *J Am Acad Dermatol* 2023; 89:1072-1074.

Aebischer V, Abu-Ghazaleh A, Metzler G, Riedl L, Garbe C, Flatz L, Eigentler T, Forchhammer S. Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage. *Pigment Cell Melanoma Res* 2023; 36:512-521.

Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuera L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. *EBioMedicine* 2023; 93:104644.

Troesch A, Hoellwerth M, Forchhammer S, Del Regno L, Lodde G, Turko P, Cheng F, Levesque M, Hadaschik E, Livingstone E, Peris K, Flatz L, Koelblinger P, Dummer R, Dimitriou F. The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. *J Eur Acad Dermatol Venereol* 2023; 37:922-931.

Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Foo F, Wever R, Flatz L, Eggermont A, Forchhammer S. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). *Eur J Cancer* 2022; 182:155-162.

Gassenmaier M, Häfner H, Hahn M, Kofler L, Wagner N, Forchhammer S. Histological and Immunohistochemical Changes of Congenital Melanocytic Nevi With Age. *Am J Dermatopathol* 2021; 43:707-713.

Gassenmaier M, Hahn M, Metzler G, Bauer J, Yazdi A, Keim U, Garbe C, Wagner N, Forchhammer S. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. *Cancers (Basel)* 2021; 13

Bochem J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. *J Immunother Cancer* 2021; 9

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch